No Data
JINHAI MED TECH (02225.HK) expects an annual loss of approximately 18.1 million Singapore dollars.
On March 21, GELONGHUI reported that JINHAI MED TECH (02225.HK) announced the group is expected to record a net loss of approximately 18.1 million Singapore dollars for the year ending December 31, 2024, compared to a net loss of about 4.1 million Singapore dollars in the previous year. The Board of Directors believes the group's Business will show stable development in the fiscal year 2024. The group expects to achieve revenue of approximately 50.2 million Singapore dollars and a gross profit of about 11.4 million Singapore dollars for the fiscal year 2024, whereas the revenue for the fiscal year 2023 was about 45.6 million Singapore dollars and gross profit was approximately 12 million Singapore dollars.
Jinhai Medical Technology Issues Profit Warning Amid Rising Expenses
JINHAI MED TECH: PROFIT WARNING
JINHAI MED TECH (02225.HK) will hold a Board of Directors meeting on March 28 to consider and approve the annual performance.
Glory Exchange announced on March 14 that JINHAI MED TECH (02225.HK) will hold a Board of Directors meeting on March 28, 2025, aimed at considering and approving the announcement of the annual performance for the company and its subsidiaries for the year ending December 31, 2024, as well as the distribution of the final dividend (if applicable).
JINHAI MED TECH: DATE OF BOARD MEETING
Hong Kong stock movement | JINHAI MED TECH (02225) rose over 17% in early trading as the company partners with Sinopharm Lingbusiness to accelerate the commercialization process.
JINHAI MED TECH (02225) surged over 17% in the early session, as of the time of writing, it increased by 11.81%, reported at 1.42 Hong Kong dollars, with a transaction amount of 2.3867 million Hong Kong dollars.
There's Reason For Concern Over Jinhai Medical Technology Limited's (HKG:2225) Massive 31% Price Jump
